Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts

Nimura, 2000, Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience, J Hepatobiliary Pancreat Surg, 7, 155, 10.1007/s005340050170 Nagakawa, 2002, Biliary tract cancer treatment: results from the biliary tract cancer. Statistics registry in Japan, J Hepatobiliary Pancreat Surg, 9, 569, 10.1007/s005340200076 Suh, 2000, Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma, Hepatology, 31, 12, 10.1002/hep.510310104 Chen, 2001, Intraductal papillary neoplasia of the liver associated with hepatolithiasis, Hepatology, 34, 651, 10.1053/jhep.2001.28199 Tajima, 2004, An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma, Br J Surg., 91, 99, 10.1002/bjs.4366 Shibahara, 2004, MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type, Hepatology, 39, 220, 10.1002/hep.20031 Miwa, 2002, Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma, Cancer, 94, 428, 10.1002/cncr.10235 Jarnagin, 2005, Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma, Ann Surg, 241, 703, 10.1097/01.sla.0000160817.94472.fd Suto, 1997, Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct, Oncology, 54, 407, 10.1159/000227727 Takao, 1999, Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis, Cancer, 86, 1966, 10.1002/(SICI)1097-0142(19991115)86:10<1966::AID-CNCR13>3.0.CO;2-M Sugimachi, 2001, The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma, J Hepatol, 35, 74, 10.1016/S0168-8278(01)00079-4 Hui, 1999, Decreased p27 (Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma, Hepatology, 30, 1167, 10.1002/hep.510300506 Albores-Saavedra, 2000, Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts, Cancer, 89, 508, 10.1002/1097-0142(20000801)89:3<508::AID-CNCR5>3.0.CO;2-D Hoang, 2002, Invasive papillary carcinomas of extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases, Mod Pathol, 15, 1251, 10.1097/01.MP.0000036450.61830.8E Hong, 2005, The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor, Am J Surg Pathol, 29, 1177, 10.1097/01.pas.0000160978.77833.d7 Zen, 2006, J Hepatol, 44, 350, 10.1016/j.jhep.2005.09.025 Zen, 2006, Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas, Hepatology, 44, 1333, 10.1002/hep.21387 Deryugina, 2006, Matrix metalloproteinases and tumor metastasis, Cancer Metastasis Rev, 25, 9, 10.1007/s10555-006-7886-9 Ii, 2006, Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis, Exp Biol Med, 231, 20, 10.1177/153537020623100103 Yamashita, 2000, Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma, Clin Cancer Res, 6, 1169 Yamamoto, 2001, Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression, J Clin Oncol, 19, 1118, 10.1200/JCO.2001.19.4.1118 Jiang, 2006, Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells, Int J Mol Med, 17, 583 Maatta, 2000, Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis, Clin Cancer Res, 6, 2726 Shirabe, 1999, Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma, Surgery, 126, 842, 10.1016/S0039-6060(99)70024-3 Sato, 1994, A matrix metalloproteinase expressed on the surface of invasive tumour cells, Nature (Lond), 370, 61, 10.1038/370061a0 Seiki, 2003, Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion, Cancer Letters, 194, 1, 10.1016/S0304-3835(02)00699-7 Itatsu, 2007, Immmunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis, Liver Int, 27, 1144, 10.1111/j.1478-3231.2007.01577.x Zen, 2005, Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement, Pathol Int, 55, 180, 10.1111/j.1440-1827.2005.01816.x Nakanuma, 1997, Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply, Microsc Res Tech, 38, 552, 10.1002/(SICI)1097-0029(19970915)38:6<552::AID-JEMT2>3.0.CO;2-H International Union Against Cancer UICC, 2002 Albores-Saavedra, 2000, Carcinoma of the gallbladder and extrahepatic bile ducts, 206 Chae, 2004, Expression of matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in intraductal and nonintraductal growth type of cholangiocarcinoma, Am J Gastroenterology, 99, 68, 10.1046/j.1572-0241.2003.04025.x Terada, 1996, Expression of immunoreactive matrix metalloproteinases in human normal livers and primary liver tumors, Hepatology, 23, 1341, 10.1002/hep.510230608 King, 2003, Randomized double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects, Anticancer Res, 23, 639 Bramhall, 2002, Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomized trial, Br J Cancer, 86, 1864, 10.1038/sj.bjc.6600310